Investors signal concern that the expiring federal EV tax credit created a 'pull-forward' of demand, raising questions about future growth.
Permanent J-Code from CMS aims to streamline reimbursement and broaden patient access for its graft-versus-host disease treatment.
Analyst confidence swells following positive FDA alignment on the company's pivotal gene therapy trial for Rett Syndrome.
Stock soars as government backing for domestic lithium production and positive sector sentiment fuel investor optimism.
Hardware manufacturer Canaan's landmark U.S. order and Cipher Mining's strategic AI partnerships fuel renewed investor confidence.
Genentech's Tecentriq combination therapy is the first maintenance treatment for extensive-stage small cell lung cancer, a significant advance in a hard-to-treat disease.
Fair Isaac's new direct-to-lender model threatens a core revenue stream for TransUnion and Equifax, sending shares sharply lower.
Company forecasts a $710 million revenue hit from expanded U.S. export restrictions, impacting its significant business in the Chinese market.